CVKD

+ Watchlist + Portfolio

Cadrenal Therapeutics, Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $1.63
52-Week Range: $1.58 – $14.64
Market Cap: $5.67M
P/E (TTM): —
EPS (TTM): -4.88
Dividend Yield: —

Advanced Metrics

Price/Book: 1.20
PEG Ratio: —
Return on Equity: -275.16%
Return on Assets: -125.93%
Gross Margin: 0.00%
Operating Margin: 0.00%
Profit Margin: 0.00%
Current Ratio: 3.73
Debt/Equity: —
Total Debt: $0.00
Free Cash Flow: $-8.32M
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $3.32M

CVKD Income statement, annual periods, in USD
USD	FY2023	FY2024	FY2025
Revenue	$0.00	$0.00	$0.00
Research & Development	$4.08M	$4.21M	$4.10M
Selling, General & Admin	$3.55M	$6.75M	$9.35M
Operating Expenses	$7.63M	$10.96M	$13.46M
Operating Income	-$7.63M	-$10.96M	-$13.46M
EBITDA	-$8.34M	-$10.96M	-$13.45M
Pretax Income	-$8.36M	-$10.65M	-$13.24M
Net Income	-$8.36M	-$10.65M	-$13.24M
Diluted EPS	-9.29	-8.73	-6.64
Diluted Shares	899465	1.22M	1.99M

CVKD Cash Flow statement, annual periods, in USD
USD	FY2023	FY2024	FY2025
Operating Cash Flow	-$3.53M	-$7.36M	-$12.60M
Capital Expenditure	-$3.25K	-$6.54K	-$5.10K
Free Cash Flow	-$3.53M	-$7.36M	-$12.61M
Depreciation & Amortisation	$1.98K	$1.88K	$6.87K
Stock-Based Compensation	$710.38K	$1.42M	$1.94M
Investing Cash Flow	-$3.25K	-$6.54K	-$5.10K
Financing Cash Flow	$11.90M	$8.98M	$6.60M
Share Repurchases	—	$0.00	-$291.88K
Net Change in Cash	$8.37M	$1.62M	-$6.01M

CVKD Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00
Research & Development	$1.67M	$1.08M	$688.47K	$666.32K	$771.51K
Selling, General & Admin	$2.25M	$2.66M	$2.04M	$2.40M	$1.74M
Operating Expenses	$3.93M	$3.73M	$2.73M	$3.07M	$2.51M
Operating Income	-$3.93M	-$3.73M	-$2.73M	-$3.07M	-$2.51M
EBITDA	-$3.92M	-$3.73M	-$2.73M	-$3.06M	-$2.51M
Pretax Income	-$3.85M	-$3.67M	-$2.69M	-$3.04M	-$2.50M
Net Income	-$3.85M	-$3.67M	-$2.69M	-$3.04M	-$2.50M
Diluted EPS	-2.09	-1.87	-1.31	—	-1.04
Diluted Shares	1.84M	1.96M	2.04M	—	2.41M

CVKD Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$7.34M	$5.57M	$3.86M	$4.01M	$2.31M
Receivables	$24.66K	$19.04K	$12.79K	$5.10K	$5.47K
Current Assets	$7.94M	$5.97M	$4.08M	$4.32M	$2.86M
Total Assets	$7.95M	$5.98M	$4.09M	$4.33M	$2.86M
Current Liabilities	$1.84M	$1.68M	$1.35M	$1.59M	$1.06M
Total Liabilities	$1.84M	$1.68M	$1.35M	$1.59M	$1.06M
Retained Earnings	-$29.57M	-$33.24M	-$35.92M	-$38.96M	-$41.46M
Shareholders' Equity	$6.11M	$4.30M	$2.73M	$2.74M	$1.80M
Working Capital	$6.10M	$4.29M	$2.73M	$2.73M	$1.79M

CVKD Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$4.65M	-$3.03M	-$2.36M	-$2.57M	-$3.00M
Capital Expenditure	-$3.25K	—	-$1.85K	—	—
Free Cash Flow	-$4.65M	-$3.03M	-$2.36M	-$2.57M	-$3.00M
Depreciation & Amortisation	$5.52K	$401.00	$401.00	$555.00	$555.00
Stock-Based Compensation	$548.76K	$592.64K	$473.38K	$325.10K	$252.36K
Investing Cash Flow	-$3.25K	$0.00	-$1.85K	$0.00	$0.00
Financing Cash Flow	$1.97M	$1.26M	$648.36K	$2.72M	$1.30M
Net Change in Cash	-$2.68M	-$1.77M	-$1.71M	$147.71K	-$1.70M

Market Snapshot

About

Cadrenal Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies for kidney disease and related conditions. The company's research programs target treatments for acute kidney injury, chronic kidney disease, and complications arising from renal dysfunction. Cadrenal Therapeutics pursues novel drug candidates designed to protect kidney function and improve outcomes for patients with renal disorders. The company operates in the nephrology pharmaceutical sector, addressing a significant unmet medical need given the prevalence of kidney disease worldwide.